On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer ...
Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now ...
First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology "Scientists can now ...
Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...
Hosted on MSN
TXG Q3 Deep Dive: Spatial Biology and Consumables Drive Outperformance Amid Macro Uncertainty
Biotech company 10x Genomics (NASDAQ:TXG) in Q3 CY2025, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the midpoint) was ...
PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS) ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results